These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
614 related articles for article (PubMed ID: 21166737)
1. Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis. Wang F; Lv ZS; Fu YK Dis Esophagus; 2011 Jul; 24(5):318-24. PubMed ID: 21166737 [TBL] [Abstract][Full Text] [Related]
2. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Anderson LA; Johnston BT; Watson RG; Murphy SJ; Ferguson HR; Comber H; McGuigan J; Reynolds JV; Murray LJ Cancer Res; 2006 May; 66(9):4975-82. PubMed ID: 16651456 [TBL] [Abstract][Full Text] [Related]
3. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Kastelein F; Spaander MC; Biermann K; Steyerberg EW; Kuipers EJ; Bruno MJ; Gastroenterology; 2011 Dec; 141(6):2000-8; quiz e13-4. PubMed ID: 21878200 [TBL] [Abstract][Full Text] [Related]
4. Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus. Thrift AP; Anderson LA; Murray LJ; Cook MB; Shaheen NJ; Rubenstein JH; El-Serag HB; Vaughan TL; Schneider JL; Whiteman DC; Corley DA Am J Gastroenterol; 2016 Nov; 111(11):1528-1535. PubMed ID: 27575711 [TBL] [Abstract][Full Text] [Related]
5. Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma. Tsibouris P; Hendrickse MT; Isaacs PE Aliment Pharmacol Ther; 2004 Sep; 20(6):645-55. PubMed ID: 15352913 [TBL] [Abstract][Full Text] [Related]
6. Determination of risk for Barrett's esophagus and esophageal adenocarcinoma. Thrift AP Curr Opin Gastroenterol; 2016 Jul; 32(4):319-24. PubMed ID: 27276368 [TBL] [Abstract][Full Text] [Related]
7. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of Barrett's esophagus. Schneider JL; Zhao WK; Corley DA Dig Dis Sci; 2015 Feb; 60(2):436-43. PubMed ID: 25213077 [TBL] [Abstract][Full Text] [Related]
13. The use of nonsteroidal anti-inflammatory drugs and the risk of Barrett's oesophagus. Thrift AP; Pandeya N; Smith KJ; Green AC; Webb PM; Whiteman DC Aliment Pharmacol Ther; 2011 Nov; 34(10):1235-44. PubMed ID: 21967506 [TBL] [Abstract][Full Text] [Related]
14. Incidence of adenocarcinoma among patients with Barrett's esophagus. Hvid-Jensen F; Pedersen L; Drewes AM; Sørensen HT; Funch-Jensen P N Engl J Med; 2011 Oct; 365(15):1375-83. PubMed ID: 21995385 [TBL] [Abstract][Full Text] [Related]
15. Medical decision analysis of chemoprevention against esophageal adenocarcinoma. Sonnenberg A; Fennerty MB Gastroenterology; 2003 Jun; 124(7):1758-66. PubMed ID: 12806608 [TBL] [Abstract][Full Text] [Related]
16. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Farrow DC; Vaughan TL; Hansten PD; Stanford JL; Risch HA; Gammon MD; Chow WH; Dubrow R; Ahsan H; Mayne ST; Schoenberg JB; West AB; Rotterdam H; Fraumeni JF; Blot WJ Cancer Epidemiol Biomarkers Prev; 1998 Feb; 7(2):97-102. PubMed ID: 9488582 [TBL] [Abstract][Full Text] [Related]
17. Risk factors, DNA damage, and disease progression in Barrett's esophagus. Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340 [TBL] [Abstract][Full Text] [Related]
18. Response to TNF-α Is Increasing Along with the Progression in Barrett's Esophagus. Chemnitzer O; Götzel K; Maurer L; Dietrich A; Eichfeld U; Lyros O; Jansen-Winkeln B; Hoffmeister A; Gockel I; Thieme R Dig Dis Sci; 2017 Dec; 62(12):3391-3401. PubMed ID: 29086334 [TBL] [Abstract][Full Text] [Related]
20. Medical treatment of Barrett's esophagus: can it prevent cancer? Sampliner RE Surg Oncol Clin N Am; 2009 Jul; 18(3):503-8. PubMed ID: 19500739 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]